Skip to main content
. Author manuscript; available in PMC: 2013 Dec 10.
Published in final edited form as: Exp Cell Res. 2012 Jun 8;318(16):10.1016/j.yexcr.2012.06.001. doi: 10.1016/j.yexcr.2012.06.001

Fig. 2.

Fig. 2

ROS levels are elevated in TKI-resistant breast cancer cells. SUM149 and MDA-MB-468 cells were treated with 0.5 µM gefitinib for 30min. ROS production was measured using the fluorescent dye, 2′,7′-dichlorofluorescin diacetate (DCF-DA), which measures reactive oxygen on a per cell basis. The percentage of cells positive for ROS was determined from an average of three independent experiments. Control=vehicle control treated; and gefitinib=gefitinib treated.